The first in the U.S. to receive emergency use authorization (EUA) in this younger age group, the FDA announced Friday.
The agency amended the existing EUA to include children ages 5 to 11 after the vaccine produced an immune response that was comparable to the response seen in people ages 16 to 25, and showed 91% efficacy in a small descriptive analysis.
On Tuesday, November 2, the CDC’s Advisory Committee on Immunization Practices will meet to discuss further clinical recommendations.
